BIOGEN

Analysis before buying or selling Biogen shares

Trade the Biogen share!

BUY

SELL

Your capital is at risk

Chart provided by Tradingview

Before embarking on online speculation on the share price of the American group Biogen, we offer you a summary of the stock market, financial and economic data that you should use in your analysis of this stock. We will provide you with a detailed presentation of the group's activities, its main competitors in the market and in its sector of activity, as well as its recent partnerships. Of course, we will also explain how to carry out a good fundamental analysis of this stock with the news and publications most likely to have an impact on this value.

Can I receive dividends when I buy Biogen shares?

ISIN code: US09062X1037

Ticker: NASDAQ: BIIB

Index or market: Nasdaq

How to buy and sell Biogen shares?

Open an account by clicking here

Deposit Funds

Search Biogen (NASDAQ: BIIB)

Buy/Sell Biogen shares

Your capital is at risk

Elements to consider before selling or buying Biogen shares

Analysis N°1

In particular, it is important to closely monitor the innovations made by the Biogen group with the obtaining of new patents or the advancement of clinical trial phases on drugs under development.

Analysis N°2

The partnerships that this group may set up in the future will, of course, most often also have a positive impact on the evolution of this title and should therefore be the subject of your attention.

Analysis N°3

We will of course also monitor the competition in this sector of activity with the results of other companies offering similar products and their major news.

Analysis N°4

Strategic transactions such as mergers, acquisitions or joint ventures may also have an influence on this share on the stock market.

Analysis N°5

Finally, all important communications of the group will be reviewed, including the publication of annual and quarterly financial results.

Analysis before buying or selling Biogen shares

Buy Biogen shares

Sell Biogen shares

Your capital is at risk

General presentation of Biogen

Let's now move on to another important part of your analysis of Biogen's share price, which consists of a good knowledge of the company and its various activities. Indeed, it is through this knowledge and an understanding of the sources of income of this group that you will be most likely to anticipate the growth issues of this company.

The Biogen Inc. group is an American company operating in the pharmaceutical sector. More specifically, this company is currently one of the leaders in the design, production and sale of therapeutic products worldwide.

In order to better understand the Biogen group's activities, they can be broken down into several divisions according to the share of turnover they generate :

Drug sales represent the bulk of Biogen's business and alone generate 79.2% of the company's sales. These include medicines for the treatment of multiple sclerosis, chronic adult psoriasis, rheumatoid arthritis, cancers and other diseases.
The Biogen group also generates nearly 15.9% of its revenues through the collection of royalties from the use of patents it has filed.
Finally, the remaining 4.9% of the company's turnover, i.e. 4.9%, comes from other activities and in particular a large part of the income from various partnership agreements.

Photo credits: ©diy13/123RF.COM

The major competitors of Biogen

We now propose you to discover how to make a good study of Biogen's competition by analysing the news and results of the companies that are the direct opponents of this group on the market.

TevaPharmaceuticals

This company based in Israel is indeed one of the most important pharmaceutical companies in the world but also and above all the leading producer of generic drugs in the world. This company owns several brands of medicines such as Teva but also Ratiopharm, Cephalon, Taiyo, Barr, Pliva and Ivax.

Novartis

This Swiss pharmaceutical group is another important competitor of Biogen. It has been in existence since 1996 and is the result of the merger of Ciba-Geigy and Sandoz.

Sanofi

Finally, the Sanofi group is a French company also specialising in this sector, notably with prescription drugs in the diabetes, rare diseases, multiple sclerosis and oncology sectors, consumer health products and a number of generic drugs. It also develops vaccines.

The major partners of Biogen

We now offer you an overview of the recent partnerships that the Biogen group has been able to set up and their respective objectives with two concrete examples.

Digital Pharma Lab

First of all and in 2018, the Biogen group has signed a partnership with Digital Pharma Lab, the European accelerator of pharmatech with Biogen's participation in the first season of its programme. Thanks to this partnership, Biogen is the first company in its sector to benefit from Digital Pharma Lab's acceleration programme and has even become its exclusive partner in the neurosciences field.

Theradiag

Another partnership signed this time in 2019 is the one set up with Theradiag to supply Lisa Tacker kits for monitoring Flixabi, a biosimilar of infliximab. Biogen is in fact a company specialising in the manufacture of biomedicines and has made several drugs available to France, including Flixabi, with the aim of helping to control healthcare costs. These monitoring kits will thus be offered in calls for tender in which the company is participating in France and in certain European countries, with the aim of optimising the care of patients treated with this drug.

Trade the Biogen share!

Your capital is at risk. Performance is not a guide to future performance and is not constant over time.

Frequently Asked Questions

Has the Biogen share generated dividends in recent years?

Although Biogen has experienced strong growth in recent years, for the moment it prefers to follow a policy of reinvesting its profits in its activities, particularly in R&D. For this reason, no dividend has been paid to its shareholders for the moment. However, this does not mean that this will not be the case in the years to come.

Is it compulsory to carry out a technical analysis of the Biogen action?

While, as we have seen above, good fundamental analysis can help you in taking positions on Biogen's share price, it should never be used alone unless you are considering a very short-term strategy such as an intraday strategy. It is therefore almost always essential to carry out technical analysis of the stock to maximise the relevance of your signals.

Is it easy to find Biogen's financial results online?

Yes, it is relatively easy to find the financial results of the Biogen group online since the company's official website has a section reserved for investors. You will find all the group's financial reports as well as the company's major publications and news in real time.

Trade the Biogen share!

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. {etoroCFDrisk}% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.